In a repeat setback, Neurocrine flags a failure for Tourette syndrome study — shares sink
Shares of Neurocrine $NBIX got hammered Tuesday morning after the biotech conceded that its Phase IIb study of valbenazine for Tourette syndrome had flopped.
The stock swiftly plunged more than 20% on the news.
The primary endpoint for their study was a reduction in facial tics among patients with the disease. We’re not getting to see the actual data yet to see just how bad a setback this is.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.